PHARMACOTHERAPY OF BRONCHITIS IN HAYATABAD MEDICAL COMPLEX PESHAWAR

Main Article Content

Dr Israr Ullah RPH
Dr. Roman Wazir
Dr. Huma Masroor
Nusrum Iqbal
Wasif Ullah
Dr Arif hayat

Keywords

Bronchitis, Antibiotics, ADRs, AMR

Abstract

Introduction: A condition known as bronchitis arises when the lungs’ bronchialtubes, or airways, become inflamed and produce mucus when coughed. Both acuteand chronic cases of bronchitis are possible (long-term).


Aims/objectives: The main objective of current prospective study in bronchitispatients is to evaluate antibiotics consumption, effectiveness and its escalation withantimicrobial resistance (AMR).


Methodology: Bronchit patient’s prospective data were collected during the diseasepeak season (January-March) at Hayatabad Medical Complex, Peshawar, KhyberPakhtunkhwa, Pakistan. Antibiotics consumption was calculated from the patientmedication chart, where hospital -stay/longitivity were evaluated from DOA toDOD.


Results: Highest antibiotics consumption of Piperacillin, Vancomycin, Ampicillinand Cefaperzone + Sulbactam are observed in more than 60% bronchitis in-patients. Similarly, hospital-stay/longitivity from 4-14 days were observed of 10-30% bronchitis in-patients, which is an alarming situation.


Conclusion: This condition is most likely a viral infection so antibioticsconsumption should be discouraged as it is not effective in this case and it also leads to adverse reactions and AMR.

Abstract 139 | PDF Downloads 37

References

1. Fiorentino, G., Lanza, M., Annunziata, A., &Esquinas, A. M. (2023). Airway Clearance in Conditions of High-Risk Infections: COVID-19 and Other Conditions. In Humidification in the Intensive Care Unit: The Essentials (pp. 243-255). Cham: Springer International Publishing.
2. Hussain, H. H., Ibraheem, N. T., Al-Rubaey, N. K. F., Radhi, M. M., Hindi, N. K. K., & AL-Jubori, R. H. K. (2022). A review of airborne contaminated microorganisms associated with human diseases. Medical Journal of Babylon, 19(2), 115-122. Antunes, K. H., Cassao,
3. G., Santos, L. D., Borges, S. G., Poppe, J., Goncalves, J. B., ... & De Souza, A. P. D. (2022). Airway administration of bacterial lysate OM-85 protects mice against respiratory syncytial virus infection. Frontiers in Immunology, 13, 867022.
4. Ball P. (1995). Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest, 108(2 Suppl), 43S-52S.
5. Rajabov, O. A., Oytug‘onova, S., Soatova, X., Umbarov, J., &Asadullaev, A. (2023). BRONCHITIS-CAUSES, SYMPTOMS, COMPLICATIONS AND TREATMENT METHODS. Theoretical aspects in the formation of pedagogical sciences, 2(5), 38-44.
6. Kızılırmak, D., &Yorgancıoğlu, A. (2023). Acute and Chronic Bronchitis: Diagnosis and Treatment. In Airway diseases (pp. 1-8). Cham: Springer International Publishing. Smith, A., Kardos,
7. P., Pfaar, O., Randerath, W., Riolobos, G. E., Braido, F., &Sadofsky, L. (2023). The treatment of mild upper respiratory tract infections-a position paper with recommendations for best practice. Drugs in Context, 12.
8. Smith, S. M., Fahey, T., Smucny, J., & Becker, L. A. (2014). Antibiotics for acute bronchitis. Cochrane database of systematic reviews, (3).
9. Smith, S. M., Fahey, T., Smucny, J., & Becker, L. A. (2014). Antibiotics for acute bronchitis. Cochrane database of systematic reviews, (3).
10. Kinkade, S., & Long, N. A. (2016). Acute bronchitis. American family physician, 94(7), 560-565.
11. Smith, S. M., Fahey, T., Smucny, J., & Becker, L. A. (2014).
12. Antibiotics for acute bronchitis. Cochrane database of systematic reviews, (3).

Most read articles by the same author(s)